Neumora Therapeutics, Inc. Common Stock (NMRA) Stock

Neumora Therapeutics, Inc. Common Stock (NMRA) is a Healthcare stock trading at $1.51 (as of 2026-06-18), with a market capitalization of $342.78M and a trailing P/E of -1.2. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing therapies for brain-related diseases, including neuropsychiatric and neurodegenerative disorders. Its pipeline includes navacaprant (NMRA-140) in Phase 3 for major depressive disorder, NMRA-511 in Phase 1 for agitation associated with Alzheimer’s dementia, and NMRA-266 in Phase 1 for schizophrenia and other neuropsychiatric disorders.

Valuation — source: SEC EDGAR (first-party)
Price	$1.51
Market Cap	$342.78M
P/E Ratio	-1.2
EV / EBITDA	-1.1
Price / Book	4.09
Price / Sales	44.46
DCF Value (model)	$-18.93
DCF Upside vs Price	-1353.6%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$8.34M
Net Margin	-2839.5%
Return on Equity	-314.6%
Debt / Equity	1.60
Current Ratio	5.09
Revenue Growth (YoY)	-58.1%
EPS Growth (YoY)	-5.2%

Financial Health — source: SEC EDGAR
Altman Z-Score	-9.91 (distress)

Valuation vs Sector & Industry
Stock P/E	-1.2
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-105.6%
vs Industry	-106.9%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	Siren, L.L.C. ($16.57M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Daljit Singh Aurora
Employees	110
Country	US
IPO Date	2023-09-15

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.